Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Flexion Therapeutics Inc    FLXN

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/14/2017 08/15/2017 08/16/2017 08/17/2017 08/18/2017 Date
22.69(c) 22.33(c) 22.27(c) 22.04(c) 22.12 Last
335 817 186 058 164 200 254 284 283 124 Volume
-0.61% -1.59% -0.27% -1.03% +0.36% Change
More quotes
Financials ($)
Sales 2017 4,69 M
EBIT 2017 -112 M
Net income 2017 -115 M
Finance 2017 268 M
Yield 2017 -
Sales 2018 56,2 M
EBIT 2018 -104 M
Net income 2018 -101 M
Finance 2018 203 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 92,8x
EV / Sales2018 8,90x
Capitalization 703 M
More Financials
Company
Flexion Therapeutics, Inc. is a pharmaceutical company, which focuses on the development and commercialization of novel, local therapies.The firm specializes in treatment of patients with musculoskeletal conditions including osteoarthritis.It offers products under the Zilretta brand.The company... 
More about the company
Surperformance© ratings of Flexion Therapeutics Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on FLEXION THERAPEUTICS INC
08/08 FLEXION THERAPEUTICS : reports 2Q loss
08/08 FLEXION THERAPEUTICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITI..
08/08 FLEXION THERAPEUTICS, INC. (NASDAQ : FLXN) Files An 8-K Results of Operations an..
08/08 FLEXION THERAPEUTICS INC : Results of Operations and Financial Condition, Financ..
08/08 Flexion Therapeutics Reports Second Quarter 2017 Financial Results and Recent..
08/08 FLEXION THERAPEUTICS INC : Investor Network: Flexion Therapeutics, Inc. to Host ..
08/01 Flexion Therapeutics to Report Second-Quarter 2017 Financial Results on Augus..
07/11 FLEXION THERAPEUTICS : to Hold Investor & Analyst Day Today
07/10 FLEXION THERAPEUTICS, INC. (NASDAQ : FLXN) Files An 8-K Regulation FD Disclosure
07/10 Flexion Therapeutics to Hold Investor & Analyst Day Today
More news
Sector news : Bio Therapeutic Drugs
08/17 FDA expands use of AstraZeneca/Merck ovarian cancer drug
08/15 Three CEOs resign from Trump council over Charlottesville
08/14DJHot Stocks to Watch in the U.S. and Canada
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
More sector news : Bio Therapeutic Drugs
Latest Tweets
12:05aWant the latest upgrades & downgrades for $GNCA $CNCE $FLXN $NGHC $RRD? C.. 
08/11BMO Capital Markets Reiterates Buy Rating for Flexion Therapeutics, Inc. $FLX.. 
08/11Flexion Therapeutics's buy rating reiterated at BMO Capital Markets.  
08/10Flexion Therapeutics's buy rating reiterated at Needham & Company LLC. $3.. 
08/10Flexion Therapeutics's outperform rating reiterated at Royal Bank Of Canada. .. 
More tweets
Qtime:21
News from SeekingAlpha
08/08 Flexion Therapeutics' (FLXN) CEO Mike Clayman on Q2 2017 Results - Earnings C..
08/08 Flexion Therapeutics misses by $0.09
07/11 Flexion Therapeutics (FLXN) Investor Presentation - Slideshow
07/10 Biotech Forum Daily Digest - IPO Activity Increasing, Spotlight On Flexion Th..
07/10 Flexion set for Investor Day today
Chart FLEXION THERAPEUTICS INC
Duration : Period :
Flexion Therapeutics Inc Technical Analysis Chart | FLXN | US33938J1060 | 4-Traders
Technical analysis trends FLEXION THERAPEUTICS INC
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 35,1 $
Spread / Average Target 59%
EPS Revisions
Managers
NameTitle
Michael D. Clayman President, Chief Executive Officer, CFO & Director
Patrick J. Mahaffy Chairman
Neil Bodick Chief Scientific Officer
Yamo Deniz Chief Medical Officer
Samuel D. Colella Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
FLEXION THERAPEUTICS INC15.88%703
AMGEN14.77%122 447
CELGENE CORPORATION10.22%99 812
GILEAD SCIENCES1.02%94 471
REGENERON PHARMACEUTICALS27.64%49 721
VERTEX PHARMACEUTICALS101.63%37 450